Survival in progressive systemic sclerosis with pulmonary involvement: A single-center experience in Istanbul, Turkey

Rheumatology International

Volumn 32, Issue 6, 2012, Pages 1655-1661

  Zuhur, Ferit ^a   Zuhur, Sayid Shafi ^a,b   Zuhur, Cigdem ^a   Musellim, Benan ^a   Ongen, Gul ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

^b SISLI ETFAL TRAINING AND RESEARCH HOSPITAL   (Turkey)

Author keywords

HRCT; Progressive systemic sclerosis; Pulmonary hypertension; Pulmonary involvement; Survival

Indexed keywords

CARBON MONOXIDE; COLCHICINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; HYDROXYCHLOROQUINE; METHOTREXATE; PENICILLAMINE;

ACCIDENT; ACUTE ABDOMEN; ADULT; ARTICLE; CAUSE OF DEATH; CLINICAL FEATURE; CLINICAL STUDY; DEMOGRAPHY; DISEASE SEVERITY; ECHOCARDIOGRAPHY; FEMALE; FOLLOW UP; HEART INFARCTION; HEMOPTYSIS; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HUMAN; LUNG ARTERY PRESSURE; LUNG CANCER; LUNG DISEASE; LUNG EMBOLISM; LUNG FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; PROGNOSIS; PULMONARY HYPERTENSION; RESPIRATORY FAILURE; RETROSPECTIVE STUDY; SURVIVAL RATE; SYSTEMIC SCLEROSIS; TURKEY (REPUBLIC);

ADULT; AGE OF ONSET; AGED; DISEASE PROGRESSION; ECHOCARDIOGRAPHY; FEMALE; HUMANS; HYPERTENSION, PULMONARY; KAPLAN-MEIER ESTIMATE; LUNG; LUNG DISEASES; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RESPIRATORY FUNCTION TESTS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SCLERODERMA, DIFFUSE; SURVIVAL RATE; TIME FACTORS; TOMOGRAPHY, X-RAY COMPUTED; TURKEY;

EID: 84863883133     PISSN: 01728172     EISSN: 1437160X     Source Type: Journal    
DOI: 10.1007/s00296-011-1842-x     Document Type: Article

References (29)

1. Roufosse FE, de Bellefon LM (2007) Systemic sclerosis. Acta Clin Belg 62:323-329
2. Du Bois RM (2007) Mechanisms of scleroderma-induced lung disease. Proc Am Thorac Soc 4:434-438
3. Bouros D, Wells AU, Nicholson AG, Colby TV, Polychronopoulos V, Pantelidis P (2002) Histopathologic subsets of Wbrosing alveolitis in patients with systemic sclerosis and their relationship to outcome. Am J Respir Crit Care Med 165:1581-1586
4. Benan M, Hande I, Gul O (2007) The natural course of progressive systemic sclerosis patients with interstitial lung involvement. Clin Rheumatol 26:349-354
5. Simeón CP, Armadans L, Fonollosa V, Solans R, Selva A, Villar M et al (2003) Mortality and prognostic factors in Spanish patients with systemic sclerosis. Rheumatology (Oxford) 42:71-75
6. Jacobsen S, Halberg P, Ullman S (1998) Mortality and causes of death of 344 Danish patients with systemic sclerosis. Br J Rheumatol 37(7):750-755
7. Hesselstrand R, Scheja A, Akesson A (1998) Mortality and causes of death in a Swedish series of systemic sclerosis patients. Ann Rheum Dis 57:682-686
8. Bryan C, Howard Y, Brennan P, Black C, Silman A (1996) Survival following the onset of scleroderma: results from a retrospective inception cohort study of the UK patient population. Br J Rheumatol 35:1122-1126
9. Abu-Shakra M, Lee P (1995) Mortality in systemic sclerosis: a comparison with the general population. J Rheumatol 22:2100-2102
10. Kuwana M, Kaburaki J, Arnett FC, Howard RF, Medsger TA Jr, Wright TM (1999) Influence of ethnic background on clinical and serologic features in patients with systemic sclerosis and anti-DNA topoisomerase I antibody. Arthritis Rheum 42:465-474
11. Altman RD, Medsger TA Jr, Bloch DA, Michel BA (1991) Predictors of survival in systemic sclerosis (scleroderma). Arthritis Rheum 34:403-413
12. Mayes MD, Lacey JV Jr, Beebe-Dimmer J, Gillespie BW, Cooper B, Laing TJ et al (2003) Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population. Arthritis Rheum 48:2246-2255
13. Steen VD, Medsger TA (2007) Changes in causes of death in systemic sclerosis, 1972-2002. Ann Rheum Dis 66:940-944
14. Subcoomittee for Scleroderma Criteria of tht American Rheumatism Association Diagnostic, therapeutic Criteria Committee (1980) Preliminary criteria for the classiWcation of systemic sclerosis. Arthritis Rheum 23:581-590
15. Al-Dhaher FF, Pope JE, Ouimet JM (2010) Determinants of morbidity and mortality of systemic Sclerosis in Canada. Semin Arthritis Rheum 39:269-277
16. Alamanos Y, Tsifetaki N, Voulgari PV, Siozos C, Tsamandouraki K, Alexiou GA et al (2005) Epidemiology of systemic sclerosis in northwest Greece 1981 to 2002. Semin Arthritis Rheum 34:714-720
17. Bennett R, Bluestone R, Holt PJ, Bywaters EG (1971) Survival in scleroderma. Ann Rheum Dis 30(6):581-588
18. Nishioka K, Katayama I, Kondo H, Shinkai H, Ueki H, Tamaki K (1996) Epidemiological analysis of prognosis of 496 Japanese patients with progressive systemic sclerosis (SSc). Scleroderma Research Committee Japan. J Dermatol 23:677-682
19. Abu-Shakra M, Guillemin F, Lee P (1993) Cancer in systemic sclerosis. Arthritis Rheum 36:460-464
20. Koh ET, Lee P, Gladman DD, Abu-Shakra M (1996) Pulmonary hypertension in systemic sclerosis: an analysis of 17 patients. Br J Rheumatol 35:989-993
21. Trad S, Amoura Z, Beigelman C, Haroche J, Costedoat N, Boutin le TH (2006) Pulmonary arterial hypertension is a major mortality factor in diVuse systemic sclerosis, independent of interstitial lung disease. Arthritis Rheum 54:184-191
22. Williams MH, Das C, Handler CE, Akram MR, Davar J, Denton CP (2006) Systemic sclerosis associated pulmonary hypertension: improved survival in the current era. Heart 92:926-932
23. Pope JE, Lee P, Baron M, Dunne J, Smith D, Docherty PS et al (2005) Prevalence of elevated pulmonary arterial pressures measured by echocardiography in a multicenter study of patients with systemic sclerosis. J Rheumatol 32:1273-1278
24. Hill CL, Nguyen AM, Roder D, Roberts-Thomson P (2003) Risk of cancer in patients with scleroderma: a population based cohort study. Ann Rheum Dis 62:728-731
25. Rosenthal AK, McLaughlin JK, Linet MS, Persson I (1993) Scleroderma and malignancy: an epidemiological study. Ann Rheum Dis 52:531-533
26. Goh NS, Veeraraghavan S, Desai SR, Cramer D, Hansell DM, Denton CP (2007) Bronchoalveolar lavage cellular proWles in patients with systemic sclerosis-associated interstitial lung disease are not predictive of disease progression. Arthritis Rheum 56: 2005-2012
27. Tashkin DP, ElashoV R, Clements PJ, Goldin J, Roth MD, Furst DE et al (2006) Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 354:2655-2666
28. Jacobsen S, Ullman S, Shen GQ, Wiik A, Halberg P (2001) Influence of clinical features, serum antinuclear antibodies, and lung function on survival of patients with systemic sclerosis. J Rheumatol 28:2454-2459
29. Fischer A, Swigris JJ, Groshong SD, Cool SD, Sahin H, Lynch DA (2008) Clinically signiWcant interstitial lung disease in limited scleroderma: histopathology, clinical features and survival. Chest 134:601-605